Evidence map›Paper›PMID 24618150›Full record

GuidelineAnnals of oncology : official journal of the European Society for Medical Oncology2014

Vaccination for seasonal influenza in patients with cancer: recommendations of the Italian Society of Medical Oncology (AIOM).

P Pedrazzoli, F Baldanti, I Donatelli, M R Castrucci, F Puglisi, N Silvestris, S Cinieri, Italian Society of Medical Oncology

Open access · bronzeAbstract readPractice Guideline
In one paragraph

Guideline in Annals of oncology : official journal of the European Society for Medical Oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 2 pooled it
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 38 citations in OpenAlex.

  1. Guideline
  2. Influenza vaccines in immunosuppressed adults with cancer.The Cochrane database of systematic reviews · 2018
    Pooled it
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Observational
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 3 countries.

P PedrazzoliDivision of Medical Oncology, Department of Hemato-oncology p.pedrazzoli@smatteo.pv.it.
F BaldantiMolecular Virology Unit, Virology, Department of Microbiology, IRCCS Policlinico 'San Matteo' Foundation, Pavia.
I DonatelliDepartment of Infectious, Parasitic and Immune-Mediated Diseases, Istituto Superiore di Sanità, Rome.
M R CastrucciDepartment of Infectious, Parasitic and Immune-Mediated Diseases, Istituto Superiore di Sanità, Rome.
F PuglisiDepartment of Oncology, University Hospital of Udine, Udine.
N SilvestrisDivision of Medical Oncology, 'Giovanni Paolo II' Cancer Institute, Bari.
S CinieriMedical Oncology Division and Breast Unit, Sen. Antonio Perrino Hospital, Brindisi, Italy.
Italian Society of Medical Oncology
Istituto Superiore di Sanità · ITCancer Institute (WIA) · INOspedale A. Perrino · ITPoliclinico San Matteo Fondazione · ITShiraz University of Medical Sciences · IRUniversity of Udine · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundInfluenza virus causes annual epidemics in the winter-spring season with significant morbidity in the general population and important mortality in high-risk groups, including cancer patients. Opinions on the suitability of patients with malignancies not undergoing active treatment and in different phases of antineoplastic therapy, to receive influenza vaccination, vary considerably among oncologists, sometimes even within one center.

methodsWe reviewed available data, including recommendations by national health authorities, on impact of influenza in patients with cancer and their capacity to mount protective immunological responses to vaccination, thus allowing, on behalf of Italian Association of Medical Oncology, to make suitable recommendations for the prevention and treatment of seasonal influenza. RESULTS AND DISCUSSION: Patients with cancer often have disease- or treatment-related immunosuppression, and as a consequence, they may have a suboptimal serologic response to influenza vaccination. The protective effect of the different preparations of influenza vaccines in patients with cancer has not been widely investigated, especially in adult patients harboring solid tumors. The optimal timing for administration of influenza vaccines in patients receiving chemotherapy is also not clearly defined. However, since vaccination is the most effective method, along with antiviral drugs in selected patients, for preventing influenza infection, it has to be recommended for cancer patients. Implementing vaccination of close contacts of oncology patients would be an additional tool for enhancing protection in fragile patient populations.

Indexed as

Influenza VaccinesNeoplasmsHumansInfluenza, HumanVaccinationInfluenza Vaccinescancerinfluenzavaccination

Identifiers

PMID24618150
PMCPMC7109906
OpenAlexW2106914851

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.